The alliance that had been closed in 2015 with the support of Ascenion, aims to develop the company’s unique CAR-CIK technology in combination with the MDC’s proprietary Sleeping Beauty (SB) gene transfer system for the immunotherapy of cancer. The approach has the potential to overcome commercial limitations related to existing CAR-T therapies by allowing production from allogeneic donors for an off-the-shelf product, non-viral gene transfer, multifunctional 'killing' mechanisms and enhanced safety based on prior clinical data. The merger was accompanied by a $6 million lead investment in CoImmune's series A financing to fund the CAR-CIK program.
Further information: